The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control
Abstract
Despite U.S. Food and Drug Administration (FDA) approval of over 40 new treatment options for type 2 diabetes since 2005, the latest data from the National Health and Nutrition Examination Survey show that the proportion of patients achieving glycated hemoglobin (HbA1c) <7.0% (<53 mmol/mol) remains around 50%, with a negligible decline between the periods 2003–2006 and 2011–2014. The Healthcare Effectiveness Data and Information Set reports even more alarming rates, with only about 40% and 30% of patients achieving HbA1c <7.0% (<53 mmol/mol) in the commercially insured (HMO) and Medicaid populations, respectively, again with virtually no change over the past decade. A recent retrospective cohort study using a large U.S. claims database explored why clinical outcomes are not keeping pace with the availability of new treatment options. The study found that HbA1c reductions fell far short of those reported in randomized clinical trials (RCTs), with poor medication adherence emerging as the key driver behind the disconnect. In this Perspective, we examine the implications of these findings in conjunction with other data to highlight the discrepancy between RCT findings and the real world, all pointing toward the underrealized promise of FDA-approved therapies and the critical importance of medication adherence. While poor medication adherence is not a new issue, it has yet to be effectively addressed in clinical practice—often, we suspect, because it goes unrecognized. To support the busy health care professional, innovative approaches are sorely needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Physician Communication and Patient Adherence to Treatment: A Meta-Analysis
Haskard Zolnierek, K. B., & DiMatteo, M. R. (2009) · Medical Care · doi:10.1097/mlr.0b013e31819a5acc · Cited by 2,489
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220 · cited 1×
“In retrospective studies of persistence, the permissible gap after the last expected refill date often extends up to 90 days (39,40).”
BackgroundThe National Committee for Quality Assurance
Iglehart, J. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351322 · Cited by 1,824
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Research works printed but not linked: 1
- Burgess, 2009, Patients’ motivations for participating in cardiovascular clinical trials: a local perspective, Cardiovasc J Afr, 20, 220
Cited by
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & Skolnik, N. S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0805-y · Cited by 714
Šoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0888 · Cited by 242
Karter, A. J., Parker, M. M., Moffet, H. H., Gilliam, L. K., & Dlott, R. (2021) · JAMA · doi:10.1001/jama.2021.6530 · Cited by 191
Gong, E., Baptista, S., Russell, A., Scuffham, P., Riddell, M., Speight, J., Bird, D., Williams, E., Lotfaliany, M., & Oldenburg, B. (2020) · Journal of Medical Internet Research · doi:10.2196/20322 · Cited by 159
“However, clinical outcomes have not improved significantly despite considerable investment and advances in treatments and technologies over this period [2].”
BackgroundTarumi, S., Takeuchi, W., Chalkidis, G., Rodriguez-Loya, S., Kuwata, J., Flynn, M., Turner, K. M., Sakaguchi, F. H., Weir, C., Kramer, H., et al. (2021) · Methods of Information in Medicine · doi:10.1055/s-0041-1728757 · Cited by 84
Lipska, K. J., Parker, M. M., Moffet, H. H., Huang, E. S., & Karter, A. J. (2018) · JAMA · doi:10.1001/jama.2018.7993 · Cited by 76
Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study
Patel, S., Abreu, M., Tumyan, A., Adams-Huet, B., Li, X., & Lingvay, I. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000761 · Cited by 56
Hangaard, S., Laursen, S. H., Andersen, J. D., Kronborg, T., Vestergaard, P., Hejlesen, O., & Udsen, F. W. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211064633 · Cited by 55
Yale, J.-F., Bodholdt, U., Catarig, A.-M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002619 · Cited by 50
Zhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49
“This phenomenon of β-cell rest was also observed in previous studies of GLP-1 (7-36) and exendin-4 in the postprandial state (23–25).”
BackgroundResultGiugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
“Medication non-adherence may also contribute for up to 75% to the gap between clinical efficacy from randomized controlled trials and real world results in lowering A1C levels [23, 24].”
BackgroundOfori‐Asenso, R., Sahle, B. W., Chin, K. L., Mazidi, M., Ademi, Z., De Bruin, M. L., & Liew, D. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3350 · Cited by 44
Del Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43
Effect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care
Simonson, G. D., Bergenstal, R. M., Johnson, M. L., Davidson, J. L., & Martens, T. W. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821998724 · Cited by 37
Advances in GLP-1 treatment: focus on oral semaglutide
Eliaschewitz, F. G., & Canani, L. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00713-9 · Cited by 34
Pai, Y., Chen, I., Lin, J., Chen, X., Chen, H., Chang, M., Huang, J., & Lin, C. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15918 · Cited by 26
Liu, F., Li, J., Li, X., Yang, Z., Wang, W., Zhao, L., Wu, T., Huang, C., & Xu, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1405770 · Cited by 22
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Mottalib, A., Tomah, S., Hafida, S., Elseaidy, T., Kasetty, M., Ashrafzadeh, S., & Hamdy, O. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13478 · Cited by 15
“Furthermore, the real-world nature of this study contributes to minimizing the discrepancies in effectiveness that are frequently noted between clinical trials and real-world clinical practice.(36) In conclusion, patients with T1D and obesity who undergo an IMWM within real-world clinical practice were able to achieve…”
BackgroundChew, B.-H., Fernandez, A., & Sazlina, S.-G. (2018) · Psychology Research and Behavior Management · doi:10.2147/prbm.s117224 · Cited by 14
“28–31 Notwithstanding the influence that the family, social, economic and political environments have on personal health goals and behaviors; 32–35 the quality of health systems 36,37 and physician–patient communication in clinical consultations may also influence health behaviors and affect…”
Tarumi, S., Takeuchi, W., Qi, R., Ning, X., Ruppert, L., Ban, H., Robertson, D. H., Schleyer, T., & Kawamoto, K. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104001 · Cited by 12
Metadata
- Authors
- Edelman, S. V., & Polonsky, W. H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-08-11
- Volume
- 40
- Issue
- 11
- Pages
- 1425-1432
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2745170751
- Cited by
- 285
- References
- 44
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.